Chip Testing Automation: 1 Stock Set for Many Years of Double-Digit Growth

Aehr Test Systems is diversifying beyond its concentrated EV SiC wafer-level burn-in testing business—five customers accounted for 97%, 93% and 77% of sales in fiscal 2023–2025—by winning multiple orders from a "world-leading hyperscaler" to test AI processors on its Sonoma platform. Wall Street projects revenue growth of ~35% in fiscal 2027 and 26% in fiscal 2028, while stronger-than-expected results at Teradyne and Advantest and comments from ON Semiconductor about SiC stabilization support a potential cyclical recovery; customer concentration and EV demand risk remain, but the hyperscaler win materially improves AEHR's revenue mix and could act as a near-term catalyst.

Analysis

Market structure: AEHR is a direct beneficiary if WLBI demand pivots from SiC (EV) to AI processors — hyperscalers and AI-chipmakers (and equipment leaders TER/Advantest) are winners; pure EV SiC cyclical suppliers are the near-term losers if EV adoption keeps lagging. Wall Street’s 35%/26% revenue growth embedded for AEHR in FY27/28 implies material re-rating risk/reward; leading indicators from Teradyne/Advantest point to rising late-cycle test demand, tightening the supply of test-capacity and supporting pricing power for niche WLBI vendors.

Risk assessment: Key tail risks are customer-concentration failure (top-5 customers = ~77% in FY25) — a single hyperscaler order cut could remove 30–60% of expected near-term revenue — and an AI-capex retrenchment (30–50%) if valuations wobble. Immediate risk (days-weeks) centers on order-announcement volatility and guidance; medium-term (3–12 months) on hyperscaler product ramps; long-term (12+ months) on secular adoption and margin scaling. Watch hidden deps: per-device qualification cycles, platform compatibility, and fill-rates that can delay revenue recognition.

Trade implications: Establish a high-conviction tactical long AEHR (2–3% portfolio) with 12–18 month horizon, hedged with a 30% OTM 9–12 month put (or buy 12-month LEAPS calls ~25–40% OTM to lever upside). Add 1–2% long TER to capture upstream test demand and consider a pair trade: long AEHR / short ON on a 1:1 notional for 6–12 months if EV spend softens; trim AEHR at +50% and cut at -30% or if hyperscaler orders are cancelled.

Contrarian angles: Consensus underprices execution and concentration risk — the market may be underestimating how thin AEHR’s margin of safety is if a single hyperscaler pauses. Historical parallels: equipment cycles (memory/AI hype 2017–19) showed early winners can lag as OEMs consolidate; unintended consequence — rapid capacity adds by hyperscalers could saturate WLBI demand and compress tool pricing. Monitor: AEHR order backlog, number of unique hyperscaler customers, TER/Advantest book-to-bill and ON SiC guidance over next 2 quarters.

Key Decisions for Investors

• Establish a 2–3% long position in AEHR with a 12–18 month horizon; hedge by buying a 9–12 month put ~30% OTM for downside protection or purchase 12-month LEAPS calls ~25–40% OTM to leverage upside; take profit at +50% and stop-loss at -30% or on cancellation of hyperscaler orders.
• Add a 1–2% long position in TER to capture upstream AI-led test demand; hold 6–12 months and increase if TER prints consecutive beat-and-raise results (two quarters) confirming durable AI capex.
• Execute a relative-value pair: long AEHR vs short ON on a 1:1 notional for 6–12 months to express conviction that AI WLBI upside will outpace EV SiC; unwind if AEHR order backlog growth decelerates for two sequential quarters or ON raises SiC guidance by >20%.
• If seeking income or lower volatility while long AEHR, sell 6–12 week covered calls at ~10–15% OTM monthly to collect premium; only do this if willing to be called away at that cap. Monitor weekly: AEHR press releases, TER/Advantest earnings, and ON guidance — any negative comment on hyperscaler spend should trigger immediate risk reduction of 50%.